What is claimed is:

1. An isolated anti-IL-17F antibody, or an antigen-binding fragment thereof, wherein said antibody comprises:

(a) a V_H CDRl region comprising the amino acid sequence of SEQ ID NO: 45, 48, 51, 64, 67 or 70;

(b) a V_H CDR2 region comprising the amino acid sequence of SEQ ID NO: 46, 49, 52, 54, 62, 65, 68, 71 or 73;

(c) a V_H CDR3 region comprising the amino acid sequence of SEQ ID NO: 47, 50, 53, 55, 63, 66, 69 or 72;

(d) a V_L CDRl region comprising the amino acid sequence of SEQ ID NO: 74, 77, 80, 85, 91 or 94;

(e) a V_L CDR2 region comprising the amino acid sequence of SEQ ID NO: 75, 78, 81, 83, 86, 92 or 96; and

(f) a V_L CDR3 region comprising the amino acid sequence of SEQ ID NO: 76, 79, 82, 84, 93, 95, 97, 98 and 99.

2. The antibody, or antigen-binding fragment, of claim 1, which does not bind the IL-17A homodimer.

3. The antibody, or antigen-binding fragment, of claim 1, which is an IgG isotype.

4. The antibody, or antigen-binding fragment, of claim 1, wherein said antibody is an IgG1, IgG3 or IgG4 isotype.

5. The antibody, or antigen-binding fragment, of claim 4, which is monoclonal.

6. The antibody, or antigen-binding fragment, of claim 5, which is human, humanized or chimeric.

7. The antibody, or antigen-binding fragment, of any one of claims 1 to 6, which comprises a heavy chain variable region sequence having at least 95% sequence identity to an amino acid sequence selected from SEQ ID NO: 10, 14, 18, 22, 26, 30, 34, 38 and 42, and a light chain variable region sequence having at least 95% sequence identity to an amino acid sequence selected from SEQ ID NO: 12, 16, 20, 24, 28, 32, 36, 40 and 44.

8. The antibody, or antigen-binding fragment, of claim 7, which comprises a heavy chain variable region sequence comprising an amino acid sequence selected from SEQ ID NO: 10, 14, 18, 22, 26, 30, 34, 38 and 42, and a light chain variable region sequence

comprising the amino acid sequence selected from SEQ ID NO: 12, 16, 20, 24, 28, 32, 36, 40 and 44.

9. An isolated antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 10, 14, 18, 22, 26, 30, 34, 38 or 42 and a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 12, 16, 20, 24, 28, 32, 36, 40 or 44, wherein said antibody binds IL-17F.

10. An isolated anti-IL-17F antibody, or an antigen-binding fragment thereof, wherein said antibody comprises: (a) a V_H CDR1 region comprising the amino acid sequence of SEQ ID NO: 45; a V_H CDR2 region comprising the amino acid sequence of SEQ ID NO: 46; a V_H CDR3 region comprising the amino acid sequence of SEQ ID NO: 47; a V_L CDR1 region comprising the amino acid sequence of SEQ ID NO: 74; a V_L CDR2 region comprising the amino acid sequence of SEQ ID NO: 75; and a V_L CDR3 region comprising the amino acid sequence of SEQ ID NO: 76.

11. The antibody, or antigen-binding fragment, of claim 10, which does not bind the IL-17A homodimer.

12. The antibody, or antigen-binding fragment of claim 10, wherein said antibody comprises a heavy chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10 and a light chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12 or 103.

13. The antibody, or antigen-binding fragment of claim 10, wherein said antibody comprises a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 12 or 103.

14. An isolated antibody comprising a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 12 or 103, or an antigen-binding fragment thereof.

15. The antibody, or antigen-binding fragment, of claim 10 or claim 13, which is an IgG isotype.

16. The antibody of claim 15, wherein said antibody is an IgG1, IgG3 or IgG4 isotype.

17. The antibody, or antigen-binding fragment, of any one of claims 10 to 16, which is monoclonal.

18. The antibody, or antigen-binding fragment, of claim 17, which is human, humanized or chimeric.

19. A pharmaceutical composition comprising the antibody, or antigen-binding fragment, of any of claims 1 to 17 and a carrier.

20. Use of an antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 17 in the preparation of a medicament for alleviation of a symptom of an autoimmune disease or inflammatory disorder in a subject.

21. The use of claim 20, wherein said subject is a human.

22. Use of an antibody, or antigen binding fragment thereof, according to any one of claims 1 to 17, in the preparation of a medicament for treating rheumatoid arthritis, Crohn's disease, psoriasis, multiple sclerosis, chronic obstructive pulmonary disease, ulcerative colitis or asthma in a subject.

23. The use of claim 22, wherein said subject is a human.

24. Use of an antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 17 in the preparation of a medicament for treating, ameliorating, or delaying the progression of an inflammatory arthritic condition in a subject.

25. The use of claim 24, wherein said subject is a human.

26. The use or claim 25, wherein the inflammatory arthritic condition is rheumatoid arthritis.

What is claimed is:

1. An isolated anti-IL-17F antibody, or an antigen-binding fragment thereof, wherein said antibody comprises:

(a) a VH CDR1 region of SEQ ID NO: 45, a VH CDR2 region of SEQ ID NO: 46, a VH CDR3 region of SEQ ID NO: 47, and a VL CDR1 region of SEQ ID NO: 74, a VL CDR2 region of SEQ ID NO: 75 and a VL CDR3 region of SEQ ID NO: 76; or

(b) a VH CDR1 region of SEQ ID NO: 48, a VH CDR2 region of SEQ ID NO: 49, a VH CDR3 region of SEQ ID NO: 50, and a VL CDR1 region of SEQ ID NO: 77, a VL CDR2 region of SEQ ID NO: 78 and a VL CDR3 region of SEQ ID NO: 79; or

(c) a VH CDR1 region of SEQ ID NO: 51, a VH CDR2 region of SEQ ID NO: 52, a VH CDR3 region of SEQ ID NO: 53, and a VL CDR1 region of SEQ ID NO: 80, a VL CDR2 region of SEQ ID NO: 81 and a VL CDR3 region of SEQ ID NO: 82; or

(d) a VH CDR1 region of SEQ ID NO: 48, a VH CDR2 region of SEQ ID NO: 54, a VH CDR3 region of SEQ ID NO: 55, and a VL CDR1 region of SEQ ID NO: 77, a VL CDR2 region of SEQ ID NO: 83 and a VL CDR3 region of SEQ ID NO: 84; or

(e) a VH CDR1 region of SEQ ID NO: 56, a VH CDR2 region of SEQ ID NO: 62, a VH CDR3 region of SEQ ID NO: 63, and a VL CDR1 region of SEQ ID NO: 91; a VL CDR2 region of SEQ ID NO: 92; and a VL CDR3 region of SEQ ID NO: 93; or

(f) a VH CDR1 region of SEQ ID NO: 67, a VH CDR2 region of SEQ ID NO: 68, a VH CDR3 region of SEQ ID NO: 69, and a VL CDR1 region of SEQ ID NO: 80, a VL CDR2 region of SEQ ID NO: 96 and a VL CDR3 region of SEQ ID NO: 97; or

(g) a VH CDR1 region of SEQ ID NO: 70, a VH CDR2 region of SEQ ID NO: 71, a VH CDR3 region of SEQ ID NO: 72, and a VL CDR1 region of SEQ ID NO: 85, a VL CDR2 region of SEQ ID NO: 86 and a VL CDR3 region of SEQ ID NO: 98; or

(h) a VH CDR1 region of SEQ ID NO: 48, a VH CDR2 region of SEQ ID NO: 73, a VH CDR3 region of SEQ ID NO: 50, and a VL CDR1 region of SEQ ID NO: 77, a VL CDR2 region of SEQ ID NO: 78 and a VL CDR3 region of SEQ ID NO: 99.

2. The antibody, or antigen-binding fragment, of claim 1, which does not bind the IL- 17A homodimer.

3. The antibody, or antigen-binding fragment, of claim 1, which is an IgG isotype.

4. The antibody, or antigen-binding fragment, of claim 3, which is an IgGl, IgG3 or IgG4 isotype.

ooo

5. The antibody, or antigen-binding fragment, of any one of claims 1 to 4, which is monoclonal.

6. The antibody, or antigen-binding fragment, of claim 5, which is human, humanized, bispecific or chimeric.

7. The antibody, or antigen-binding fragment, of claim 5, which comprises

(a) a heavy chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10 and a light chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12 or 103; or

(b) a heavy chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 14 and a light chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16; or

(c) a heavy chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 18 and a light chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20; or

(d) a heavy chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 22 and a light chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24; or

(e) a heavy chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 26 and a light chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 28; or

(f) a heavy chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 34 and a light chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 36; or

(g) a heavy chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 38 and a light chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40; or

(h) a heavy chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 42 and a light chain variable region sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 44.

8. The antibody, or antigen-binding fragment, of claim 7, which comprises

(a) a heavy chain variable region sequence of SEQ ID NO: 10 and a light chain variable region sequence of SEQ ID NO: 12 or 103; or

ooo

(b) a heavy chain variable region sequence of SEQ ID NO: 14 and a light chain variable region sequence of SEQ ID NO: 16; or

(c) a heavy chain variable region sequence of SEQ ID NO: 18 and a light chain variable region sequence of SEQ ID NO: 20; or

(d) a heavy chain variable region sequence of SEQ ID NO: 22 and a light chain variable region sequence of SEQ ID NO: 24; or

(e) a heavy chain variable region sequence of SEQ ID NO: 26 and a light chain variable region sequence of SEQ ID NO: 28; or

(f) a heavy chain variable region sequence of SEQ ID NO: 34 and a light chain variable region sequence of SEQ ID NO: 36; or

(g) a heavy chain variable region sequence of SEQ ID NO: 38 and a light chain variable region sequence of SEQ ID NO: 40; or

(h) a heavy chain variable region sequence of SEQ ID NO: 42 and a light chain variable region sequence of SEQ ID NO: 44.

9. The antibody, or antigen-binding fragment, of any one of claims 1 to 8, wherein said antibody does not bind the IL- 17A homodimer.

10. The antibody, or antigen-binding fragment, of claim 9, which is monoclonal.

11. The antibody, or antigen-binding fragment, of claim 10, which is human, humanized, bispecific or chimeric.

12. The antibody, or antigen-binding fragment, of claim 10, which is an IgG isotype.

13. The antibody, or antigen-binding fragment, of claim 12, which is an IgG1, IgG3 or IgG4 isotype.

14. A pharmaceutical composition, comprising the antibody, or antigen-binding fragment, of any of claims 1 to 13 and a carrier.

15. Use of an antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 13 in the preparation of a medicament for alleviation of a symptom of an autoimmune disease or inflammatory disorder in a subject.

16. The use of claim 15, wherein the subject is a human.

17. Use of an antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 13 in the preparation of a medicament for treating rheumatoid arthritis, Crohn's

disease, psoriasis, multiple sclerosis, chronic obstructive mulmonary disease, ulcerative colitis or asthma in a subject.

18. The use of claim 17, wherein said subject is a human.

19. Use of an antibody, or an antigen-binding fragment thereof, according to any one of claims 1 to 13 in the preparation of a medicament for treating, ameliorating, or delaying the progression of an inflammatory arthritis condition in a subject.

20. The use of claim 24, wherein said subject is a human.

21. The use of claim 20, wherein the inflammatory arthritic condition is rheumatoid arthritis.

ooo